164 related articles for article (PubMed ID: 31164372)
1. Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.
Aguirre AJ
Clin Cancer Res; 2019 Aug; 25(15):4589-4591. PubMed ID: 31164372
[TBL] [Abstract][Full Text] [Related]
2.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract][Full Text] [Related]
3.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract][Full Text] [Related]
5. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
[TBL] [Abstract][Full Text] [Related]
6. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.
Han J; Xu J; Liu Y; Liang S; LaBella KA; Chakravarti D; Spring DJ; Xia Y; DePinho RA
Genes Dev; 2023 Sep; 37(17-18):818-828. PubMed ID: 37775182
[TBL] [Abstract][Full Text] [Related]
7. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
8. The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
Cayron C; Guillermet-Guibert J
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101473. PubMed ID: 32593694
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
10. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer.
Carr RM; Fernandez-Zapico ME
Cancer Discov; 2020 Jul; 10(7):910-912. PubMed ID: 32611735
[TBL] [Abstract][Full Text] [Related]
11. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy.
Kong B; Bruns P; Behler NA; Chang L; Schlitter AM; Cao J; Gewies A; Ruland J; Fritzsche S; Valkovskaya N; Jian Z; Regel I; Raulefs S; Irmler M; Beckers J; Friess H; Erkan M; Mueller NS; Roth S; Hackert T; Esposito I; Theis FJ; Kleeff J; Michalski CW
Gut; 2018 Jan; 67(1):146-156. PubMed ID: 27646934
[TBL] [Abstract][Full Text] [Related]
12. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
14. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
15. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
16. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
17. Personalizing
Falcomatà C; Schneider G; Saur D
Cancer Discov; 2020 Jan; 10(1):23-25. PubMed ID: 31919121
[No Abstract] [Full Text] [Related]
18. Molecular characterisation of pancreatic ductal adenocarcinoma with
Allen MJ; Zhang A; Bavi P; Kim JC; Jang GH; Kelly D; Perera S; Denroche RE; Notta F; Wilson JM; Dodd A; Ramotar S; Hutchinson S; Fischer SE; Grant RC; Gallinger S; Knox JJ; O'Kane GM
J Clin Pathol; 2023 Mar; 76(3):158-165. PubMed ID: 34583947
[TBL] [Abstract][Full Text] [Related]
19. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract][Full Text] [Related]
20. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
